| ASA |
|---|
| Use 75-162 mg/d indefinitely (Class I, Level A) |
| 75-162 mg/d is recommended to minimize bleeding complications (Class IIa, Level B) |
| Clopidogrel |
| 75 mg/d indefinitely in ASA allergy or intolerance (Class IIa, Level B) |
| ASA + clopidogrel |
| Post STEMI (Medically managed) |
| ASA 75-162 mg/d and clopidogrel 75 mg/d for a minimum of 14 d (Class I, Level B) |
| Clopidogrel 75 mg/d may be continued for 12 mo in the absence of excess bleeding risk (Class IIa, Level C) |
| Post PCI |
| ASA 75-162 mg/d and clopidogrel 75 mg/d for 12 mo (Class I, Level B) |
| ASA 75-162 mg/d and clopidogrel 75 mg/d may be continued beyond 12 mo in patients with a high risk of thrombosis and a low risk of bleeding (Class IIa, Level C) |
| Post NSTEACS (Medically managed) |
| ASA 75-162 mg/d and clopidogrel 75 mg/d for a minimum of 1 mo (Class I, Level A) |
| Clopidogrel 75 mg/d may be continued for 12 mo in the absence of excessive bleeding risk (Class I, Level B) |
| Post PCI |
| ASA 75-162 mg/d and clopidogrel 75 mg/d for 12 mo (Class I, Level A) |
| ASA 75-162 mg/d and clopidogrel 75 mg/d may be continued beyond 12 mo in patients with a high risk of thrombosis and a low risk of bleeding (Class IIb, Level C) |
| Post CABG |
| ASA 75-162 mg/d and clopidogrel 75 mg/d for a minimum of 1 mo and up to 12 mo (Class I, Level B) |
| ASA + prasugrel |
| ASA 75-162 mg/d and prasugrel 10 mg/d for 12 mo in patients who undergo stent implantation and have an increased risk of thrombosis (eg, STEMI, history of diabetes mellitus, prior documented stent thrombosis) (Class IIa, Level B) |
| ASA 75-162 mg/d plus prasugrel 10 mg/d should be avoided in patients at a high risk of bleeding, likely to undergo CABG within 7 d, with a history of stroke or TIA, aged ≥75 y, or weight <60 kg (Class III, Level B) |
| ASA + ticagrelor |
| ASA 75-162 mg/d plus ticagrelor 90 mg twice daily for 12 mo (Class I, Level B) |
ASA, acetylsalicylic acid; CABG, coronary artery bypass grafting; NSTEACS, non–ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; TIA, transient ischemic attack.